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The balance between matrix deposition and tissue 
turnover is fundamental in wound healing. It is likely 
that the balance between proteolytic enzymes and 
their inhibitors contributes to this balance. Matrix 
metalloproteinases are clearly important in tissue 
turnover, but their roles in wound healing are poorly 
understood. To investigate this, fluid from healing 
wounds resulting from mastectomies was collected 
from 1 h to 10 d post-surgery, and was analyzed for 
tissue inhibitor of metalloproteinases-l concentra-
tions. In all cases, tissue inhibitor of metalloprotein-
ases-l levels were initially comparable t o those in 
serum, but increased rapidly to significantly higher 
levels within two days, with a tenfold average in-
crease for five patients. On the other hand, zymog-
raphy revealed that gelatinase A (72 kDa) lev els in-
ound healing involves significant synthesis, 
deposition, and degradation of extracellular 
matrix proteins. Normal tissue repair fol-
lows a sequence of inflammation, granula-
tion tissue formation, and tissue remodeling 
[1]. In chronic wounds, some aspect of this sequence is disrupted, 
resulting in delayed, . or lack of, repair. A significant part of this 
tissue turnover is probably mediated by members of the matrix 
metalloproteinases (MMPs), a family of zinc-dependent endopep-
tidases that includes collagenases, gelatinases, and stromelysins 
[2,3]. MMPs are secreted by cells as zymogens; upon activation, 
MMPs as a group are capable of degrading all major extracellular 
matrix (ECM) components, including fibrillar collagens [2,3]. 
MMPs are inhibited by specific cell-secreted proteins, tissue inhib-
itors of metalloproteinases (TIMPs), that bind the active sites of 
MMPs non-covalently, but with high affinity, resulting in an 
inactive, stoichiometric proteinase-inhibitor complex [4,5]. To 
date, three TIMPs have been identified in humans, TIMP-1, 
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creased moderately, whereas gelatinase B levels (92 
kDa) decreased an average of twofold within 4 d. In 
contrast, fluid from chronic wounds had significantly 
more gelatinolytic activity, including lower-molecu-
lar-weight proteinase species that may represent ac-
tiv ated or superactivated gelatinase fragments, as 
suggest ed by immunoprecipitation with specific an-
tibodies. Tissue inhibitor of metalloproteinases-l 
levels were lower in chronic than in healing wounds. 
These data may indicate that excess proteolysis in 
chronic wounds retards successful healing, and re-
sults from an imbalance of proteinase and inhibitors, 
as well as the presence of higher levels of activated 
metalloproteinases. K ey words: type IV collagenasel 
TIMP lhealinglextraceliular matrix. J Invest Dermatol 104: 
236-240, 1995 
TIMP-2, and TIMP-3 [6 - 8]. In this study, we have focussed our 
efforts on TIMP-1, a 28.5-kDa glycoprotein w hose amino acid and 
cDNA sequences have been determined [6,9]. The primary func-
tion of TIMP-1 is probably its inhibitory capabilities against acti-
vated MMPs. TIMP-1 has been shown to be an inhibitor of 
neovascularization [10], and to affect endothelial cell m orphogen-
esis and proliferation [11,12]. The inhibition of neovascularization 
may relate to the inhibition of gelatinases, which are known to 
degrade basement membrane collagens . Thus, TIM P-1 may play 
several roles during normal wound healing; its regulation in healing 
tissue may be critical in regulating the balance between M M P-
mediated proteolysis necessary for angiogenesis and matrix turn-
over and the deposition of newly synthesized matrix components 
necessary for tissue repair. Such a balance may be absent in cases 
where the healing process is disrupted, such as in chronic, non-
healing wounds. 
In wound healing, the spatial and temporal control of proteolysis 
is of critical importance. Both MMPs and TIMPs have been shown 
to be expressed by cells in the wound environment, and mounting 
evidence suggests that specific cell types may express these proteins 
differentially. Such seems to be the case in the remodeling cornea, 
where cell-specific and temporal expression of the two gelatinases 
varies during healing [13], as does the synthesis of collagenase and 
stromelysin [14]. It was recently shown that keratinocytes may play 
a different role in repair than do fibroblasts, producing in vivo 
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significantly more collagenase and less TIMP than fibroblasts [15]. 
Similarly, in vivo, it appears that gelatinase A localizes to fibroblasts, 
whereas gelatinase B localizes to epidermal and endothelial cells 
[16,17]. TIMP-l, whose presence would be necessary to balance 
the activity of MMPs, has been localized in bum wounds, eruptive 
xanthoma, and hypertrophic scars [18-20]. Wound fluid reflects 
some of the temporal changes in the wound environment that occur 
during healing. Chronic wound fluid has been shown to contain 
fibronectin and vitronectin degradation products indicative of 
excess proteolytic activity [21,22]. This fluid was subsequently 
shown to contain elevated levels of gelatinase A and gelatinase B 
[23]. In full-thickness incisional wounds, collagenase levels drop 
significantly during the first several days of healing [24]. Treatment 
of experimental corneal bums with a specific collagenase inhibitor 
reversed or halted the progress of ulceration, as did recombinant 
TIMP-l [25,26]. 
We have been investigating the roles of gelatinases and TIMPs in 
normal and pathologic wounds. Gelatinase A (72-kDa gelatinase, 
MMP-2) and gelatinase B (92-kDa gelatinase, MMP-9) degrade 
denatured collagens (gelatins) most effectively, in addition to 
basement membrane collagens and several other matrix proteins 
[27,28], and are secreted by numerous cells found in the wound, 
including endothelial cells, fibroblasts, keratinocytes, monocytes, 
and macrophages [2,3,27,28]. Gelatinase B is also found in specific 
granules in neutrophils, a likely source for significant quantities of 
this proteinase in the early stages of wound healing [29]. In this 
study, we show that the concentration of TIMP-l in fluid collected 
from post-surgical wounds increases within 48 h by an average of 
tenfold, with initial levels reflective of serum TIMP-l concentra-
tions. This was made possible by the development of a sensitive 
radioimmunoassay capable of quantifying TIMP-l levels in com-
plex biologic fluids. In contrast, gelatinase A levels increase mod-
erately, whereas gelatinase B levels decrease over time. Signifi-
cantly, the ratio of gelatinase to TIMP-l decreases dramatically 
within the first 48 h of wound healing, suggesting a possible change 
in proteolytic balance. Conversely, we find that chronic wound 
fluid contains elevated levels of gelatinolytic enzymes, but lower 
levels of TIMP-l. In many cases, the gelatinases were seen as 
activated and superactivated forms. 
MATERIALS AND METHODS 
Collection of Wound Fluid Fluid from healing wounds was obtained 
from the surgical drains of five women who underwent modified radical 
mastectomies. Informed consent was obtained from all patients, and the 
clinical protocols were approved by hospital Institutional Review Boards. 
The fluid was obtained beginning 1 h after the procedure, then approxi-
mately every 12 h as long as the drain was in place. The drains were 
completely emptied at each collection, ensuring that fluid obtained at the 
subsequent collection represented new wound fluid accumulated after the 
previous time point. A blood sample was collected at 1 and 24 h after 
surgery. Blood and wound fluid samples were centrifuged at 5000 rpm for 
10 min, and the supernates were stored at -70°C until analysis. All patients 
studied healed their wounds completely without complications. 
Fluid from chronic wounds was obtained from 11 patients with venous 
stasis ulcers . All patients had their wounds present for a minimum of 6 
months. Wound fluid was obtained by wringing out the Allevyn absorbent 
dressing (Smith-Kline & Nephew, UK) used to cover the wounds. Dressings 
were left on wounds until saturated; time to saturation varied in patients 
from 1 to 4 d. Fluid obtained was centrifuged and stored as above. 
Purification and Iodination of TIMP-l TIMP-1 was purified from 
medium conditioned by transformed human fibroblasts (AT2-39s), as 
described previously [30]. Purity was assessed by radioiodination in con-
junction with sodium dodecylsulfate (SDS)-polyacrylamide gel electro-
phoresis and autoradiography. Protein concentrations were determined 
using a bicinchoninic acid (BCA) assay kit (Pierce). TIMP-1 was iodinated 
oxidatively using Iodobeads (Pierce). One Iodobead was added to 100 JLI of 
0.1 M NaPi, pH 7.0, and 1.5 mCi carrier-free Na125I (15 JLI; NEN); 
iodination proceeded for 5 min. Next, 10 JLg ofTIMP-1 suspended in 20 JLI 
Hepes buffer (20 mM Hepes, 150 mM NaCl, 10% glycerol, 0.02% NaN3 , 
pH 7.5) was added, followed by a 10-min incubation. The iodination 
solution was removed from the bead and immediately separated by gel 
filtration using a s-ml disposable desalting column (Pierce) equilibrated in 
Hepes buffer. Separated material was detected by 'Y emission, pooled, and 
brought to a concentration of 1 mg/ml ovalbumin. Specific activity was 
determined by trichloroacetic acid precipitation of samples prior to gel 
filtration, and typically reached 160,000 cpm/ng. No loss of MMP inhibi-
tory activity was noted in these preparations. 
TIMP-l Radioimmunoassay Goat anti-human TIMP-1 antibody was 
developed in conjunction with Babco (Berkeley, CA) according to their 
protocols. IgG was purified by circulating diluted antiserum over Avid-AL 
resin (Bioprobe International, Inc .) according to the manufacturer's direc-
tions. Eluent was dialyzed in Hepes buffer, concentrated in the dialysis bag 
with Aquacide III (Calbiochem), and further dialyzed in Hepes buffer. 
Anti-TIMP-1 IgG was diluted to 40 JLg/ml in phosphate-buffered saline 
(PBS), and 100 ILl of this was added to individual assay wells (lmmulon 2 
removawell strips; Dynatech Laboratories). Mter a 2-h incubation at room 
temperature, wells were washed twice with PBS plus 0.1% Tween-20, then 
blocked overnight at 4°C with 300 JL13% nonfat dry milk in PBS plus 0.02% 
NaN3 . Wells were washed twice with PBS/Tween, excess liquid was 
blotted away, and 100 JLl wound fluid samples diluted fiftyfold in PBS were 
added. Labeled TIMP-1 (4 ng/well in 10 JLI) was added, and plates were 
incubated with rocking for 2 h at room temperature. The standard curve 
consisted of serially diluted TIMP-1 samples in PBS plus 1 mg/ml ovalbu-
min. After incubation, plates were washed three times with PBS/Tween and 
individual wells were analyzed by gamma counting. 
Zymography and Densitometry Wound fluid samples diluted as de-
scribed above were added to 4 X sample buffer and electrophoresed through 
gelatin-containing SDS-polyacrylamide gels, as previously described [30]. 
Mter soaking in 2.5% Triton X-100 to remove SDS, gels were incubated 
overnight in substrate buffer, stained in 0.25% Coomassie Brilliant Blue 
R-2s0 in methanol:water:acetic acid (50:40:10), then destained in 50% 
methanol [30]. Gels were then photographed, and negatives were scanned 
on an LKB densitometer to quantitate differences. Peaks were integrated by 
weighing. Gelatinase A and gelatinase B were identified by irnmunoprecipi-
tation of wound fluid samples with poyclonal antibodies raised in rabbits 
against purified gelatinases. After incubation, IgG was precipitated with 
protein G-Sepharose beads (Boehringer Mannheirn). Precipitates were 
analyzed by zymography. 
RESULTS 
TIMP-l Concentrations Vary Over Time in Wound Fluid 
Fluid from post-surgical wounds resulting from mastectomies was 
collected from five patients. This fluid was diluted fiftyfold, then 
assayed for TIMP-l concentration using a TIMP-l radioimmuno-
assay. Because of the nature of wound fluid, which includes high 
concentrations of immunoglobulins, it was decided to immobilize 
highly specific, anti-TIMP-l IgG to assay plates, and to determine 
TIMP-l concentrations in samples based on their ability to compete 
with 125I_TIMP_l for binding to immobilized IgG. This protocol 
1000 
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Figure 1. Concentrations of TIMP-l change with time in healing 
wounds. Wound fluid was collected from five mastectomy patients 
post-surgically during healing. Samples were diluted fiftyfold in PBS, then 
assayed for TIMP-1 by radioimmunoassay. Data points represent three 
separate determinations performed for each wound fluid sample (~SD) . In 
all cases, TIMP-1 levels were initially comparable to those in serum controls, 
but increased significantly within 48 h. 
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Figure 2. Gelatinolytic activity in healing wounds changes with time. Wound fluid from the five healing patients was diluted fivefold, and 7 JLlof 
each sample was analyzed by gelatin zymography. Fluid from a representative patient is illustrated here . Lanes represent the time of wound fluid collection 
in hours. Major gelatinolytic species were identified as gelatinase B (92 kDa) and gelatinase A (72 kDa). At later time points, activation products of gelatinase 
A were detected (59 kDa), but no superactivation products. Gelatinase B levels decreased to half their initial values over the time course studied. 
eliminates the need for antigen detection by secondary antibody, 
and shows a useful range between 3 and 300 ng/ml. The anti-
TIMP-l antibody used to develop this assay does not cross-react 
with TIMP-2, and recognizes TIMP-1 bound to MMPs (data not 
shown). Initial TIMP-1 levels in wound fluid samples reflected 
those found in serum, as would be expected in very early wound 
environments (Fig 1). Serum samples in these patients were 
obtained immediately postoperatively and at 24 h, and averaged 
221.2 :t 54.7 ng/ml and 230.1 :t 21.1 ng/ml, respectively. Within 
48 h, TIMP-1 concentrations in wound fluid increased up to 
twentyfold, and remained at the elevated level. Peak TIMP-1 
concentration for the five patients studied was 2391 :t 508 ng/ml. 
Though patients showed variability, the initial time course of 
post-wounding TIMP-1 increase was remarkably similar for all 
patients studied. 
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Figure 3. Gelatinase A and gelatinase B are present in wound fluid. 
Fluid from the 24-h time point of two patients (5 /-L1 diluted into 500 /-L1 PBS 
plus 1 mg/ml ovalbumin) was incubated with rabbit anti-human IgG against 
gelatinase B (92 kDa) and gelatinase A (72 kDa). Material precipitated with 
30 /-L1 protein G-agarose beads was washed three times with PBS/ovalbu-
min/O.l % Tween-20, then once with PBS alone, followed by the addition 
of non-reducing SDS sample buffer. Samples were then analyzed by gelatin 
zymography to confirm the identities of the major gelatinolytic components 
found in wound fluid. 
Gelatinase A and Gelatinase B Levels Change Differentially 
in Healing Wounds To determine the relative changes in 
gelatinase levels in wound fluid over time, samples were analyzed 
by gelatin zymography. This method resolves gelatinase A (72 kDa) 
from gelatinase B (92 kDa), and is useful in obtaining information 
about relative changes in gelatinase levels. Wound fluid from a 
typical patient is shown in Fig 2. The two major proteinases 
migrate where one would expect to see gelatinase A (72 kDa) and 
gelatinase B (92 kDa). The identities of these gelatinases were 
confirmed by immunoprecipitation with specific polyclonal anti-
bodies against these two proteins (Fig 3). Gels were photographed 
and scanned to determine the relative changes in gelatinase con-
centrations in wound fluid over time. The values obtained do not 
represent a concentration value for these proteinases, but reflect the 
relative concentration changes that occur. In all patients, gelatinase 
B levels were relatively high post-surgically, then decreased over 
time to roughly half these amounts (Fig 4). Gelatinase A levels 
increased approximately 50% within the first few days of healing, 
then did not change significantly over the remaining time studied. 
Because tissue turnover is likely to be mediated by the balance 
between proteinases and proteinase inhibitors, we were interested 
in measuring the ratios of gelatinase B to TIMP-1 for the five 
patients. Gelatinase B was selected because it appears to be the most 
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Figure 4. Gelatinases change differentially in fluid from healing 
wounds. Gelatin zymography was performed on samples obtained from the 
healing wounds of five patients, and the photographic negatives of the 
zymograms were scanned by der.sitometry. Mean values for both gelatinases 
are depicted (±SD). Note that this is a relative measurement of gel clearing, 
and does not represent actual gelatinase concentrations. GL-A, gelatinase A; 
GL-B, gelatinase B. 
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Figure 5. The ratio of gelatinase B to TIMP-l levels in healing 
wounds decreases over time. Values of relative gelatinase B levels versus 
TIMP-l concentrations were compared to determine the relative change in 
gelatinase:TIMP ratios in different samples over time. Each curve represents 
an individual patient. 
prevalent gelatinolytic enzyme present in the wound fluid, and its 
levels change much more significantly in absolute terms versus 
those of gelatinase A. Figure 5 illustrates the changing gelatinase B 
and TIMP-l levels in one patient. TIMP-l values are expressed as 
concentrations, whereas gelatinase B is expressed using values 
reflective of densitometric analysis. We sought to express the 
relative changes in gelatinase B to TIMP-l as a ratio. Because 
gelatinase B is expressed in relative activity units, no direct 
concentration ratio can be expressed. However, this ratio is useful 
in comparing different patients. In each case, the ratio of gelatinase 
B to TIMP-l was initially high, followed by a rapid decrease, 90% 
on average, within 48 h. 
Chronic Wound Fluid Contains Activated Gelatinases and 
Decreased TIMP-l Levels Chronic wound fluid from 11 pa-
tients suffering from venous stasis ulcers was analyzed for TIMP-l 
levels by radioimmunoassay. The average TIMP-l concentration 
was 952.5 ± 291.6 ng/ml, less than half the peak value found in 
healing wound fluid. When chronic wound fluid was analyzed by 
gelatin zymography, proteinase levels in a number of cases were 
significantly greater than found in the highest levels in healing 
wounds, as shown in Fig 6. More importantly, a number of 
proteolytic species of lower molecular weight were detected in 
chronic wound fluid samples. To determine if some of these bands 
200 -
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represent activated forms of the gelatinases, immunoprecipitation 
was performed. Immunoprecipitation of three of the wound-fluid 
samples using anti-gelatinase A (72 kDa) and anti-gelatinase B (92 
kDa) IgGs revealed that multiple activation or superactivation 
products of these metalloproteinases were present (Fig 7). The two 
activation products of gelatinase A (62 and 59 kDa) can be 
identified. Though identification of the lower M r bands would be 
speculation without amino acid sequence analysis, it appears that 
activation (loss of propeptides) as well as truncation has occurred to 
both gelatinases in these samples. 
DISCUSSION 
Because wound healing involves the controlled synthesis and 
degradation of ECM components, it is likely that the balance 
between proteinase and inhibitor levels plays a crucial role in the 
successful healing process. It follows that the disruption of this 
balance may lead to unsuccessful healing. In this study, we have 
analyzed the levels of gelatinase A, gelatinase B, and TIMP-l in 
fluid from healing wounds. During the first several days of healing, 
TIMP-l levels were found to increase an average of tenfold among 
the five patients studied, whereas gelatinase B levels decreased to 
half their initial values. Gelatinase A levels increased to about 50% 
above their initial values. The ratio of gelatinase B to TIMP-l 
rapidly decreased in wound fluid, suggesting that the wound 
environment shifts from one favoring tissue turnover to one 
favoring matrix deposition. Indeed, previous studies have indicated 
that most of the proteolysis occurs within the first few days of 
wound healing [24]. Other groups have previously shown that fluid 
from acute wounds contain predominantly gelatinase B, with a 
lesser amount of gelatinase A [17,23]. We performed similar 
analysis on similar samples, but included an expanded array of fluid 
samples representing the wound environment from 1 h to 10 d 
post-surgery. Our zymographic analysis illustrates that gelatinase A 
levels change moderately over time, with an increased amount of 
activated gelatinase A at later time points. In contrast, we found 
that gelatinase B levels changed significantly. In many cases, 
gelatinase B levels peaked within 48 h, then gradually decreased to 
half their peak levels. 
The cellular sources of gelatinases in the wound fluid is not yet 
known. It is possible that much of the gelatinase B is derived from 
infiltrating neutrophils that are known to migrate rapidly to wound 
sites. These cells store gelatinase B in granules [29,31], and it is 
possible that a significant proportion of this proteinase present in 
early wound fluid samples is neutrophil derived. Previous studies 
have also shown that gelatinases can be derived from tissue near the 
wound site [16,17]. Both gelatinases were found during re-epithe-
lialization in a human suction-blister model [16]. In that study, 
Figure 6. Chronic wound 
fluid contains multiple gelati-
nolytic species. Fluid obtained 
from venous stasis ulcers was di-
luted fivefold, and 7 /-Ll of each 
sample was analyzed by gelatin 
zymography. A sample represent-
ing fluid from a healing wound 
(24-h time point) is included for 
comparative purposes. Mr, molec-
ular weight markers. 
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Figure 7. Chronic wound fluid samples contain activated gelati-
nases. Wound fluids obtained from the chronic ulcers of three patients (5 
ILl diluted in 500 ILl PBS plus 1 mg/ml ovalbumin) were incubated with 10 
ILl anti-gelatinase A (anti-72) or gelatinase B (anti-92) IgG at 4°C for 2 h. 
Protein G-agarose beads (40 ILl) were added for 2 h; beads were washed 
three times in PBS plus 0.1 % Tween-20, once with PBS alone, and eluted 
with SDS sample buffer. Precipitated gelatinase was analyzed by gelatin 
zymography. Superactivation products of gelatinases lack their carboxyl 
termini, and migrate at lower Mr in SDS gels. 
gelatinase A, which increased moderately within the first 24 h 
post-wounding, was localized to fibroblasts, whereas gelatinase B, 
which increased roughly threefold within 24 h, localized to epider-
mis and endothelial cells. Similarly, the two gelatinases have been 
shown to be independently expressed during the healing of cornea 
[13]. The data presented here illustrate the longer-term changes in 
gelatinase and TIMP-l levels in healing wounds based on concen-
trations found in wound fluid. 
Chronic wound fluid from several patients was found to have 
significantly higher levels of gelatinolytic enzymes, but with lower 
TIMP-1 levels than healing wound fluid. Though gelatinase levels 
differed in the chronic wound fluids, it is significant that, in almost 
all of them, there is the presence of low-molecular-weight gelati-
nolytic species. Previous studies have shown that chronic wound 
fluid contains more gelatinase A and gelatinase B than mastectomy 
fluid, and that both activated and latent forms of these MMPs are 
present [23]. This could explain the presence of fibronectin and 
vitronectin degradation products found in chronic wound fluid 
[21,22]. Here, we observed a number of low-molecular-weight 
gelatinolytic enzymes that may represent super-activated forms of 
the gelatinases [30]. It has been shown that MMPs activate by 
cleavage of their propeptides, which contain a free cysteine that is 
thought to coordinate with the active-site zinc. It has also been 
shown that gelatinases are superactivated through the loss of their 
carboxyl domains, and that truncated gelatinase A is poorly inhib-
ited by TIMPs [30-32]. The presence of superactivated gelatinases 
in wound samples would be significant, because an active, poorly 
inhibitable enzyme would be destructive to surrounding tissue. It 
has not been previously established that this superactivation occurs 
in vivo; however, the results presented here suggest that chronic 
wounds may contain these species. When the lower levels of 
TIMP-1 in these wounds is considered, it points to the likelihood of 
an imbalance between proteinase and inhibitor levels. This imbal-
ance may lead to the degradation of matrix components, growth 
factors, and other proteins necessary for successful healing. 
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